Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business Becton Dickinson plans to spin off its Biosciences and ...

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies and GLP-1 drugs. See more here.

After a tumultuous few years, Becton, Dickinson is undergoing course correction ... This is helped by the Embecta spinoff but also by more positive expectations of the core business performance ...

(Reuters) -U.S. medical device maker Becton Dickinson is considering a potential ... care business in 2022 into a separate company, Embecta Corp, and sold its surgical instrumentation platform ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Becton Dickinson & Co., an American medical equipment company ... the spin-off of the diabetes care unit into a public company under the brand name of Embecta Corp. and she sold the surgical ...

Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The stock has a 50 day moving average of $233.08 and a two-hundred day moving average of $233.02.

In July, Embecta, a manufacturer of disposable insulin pen needles and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from ...

"Building on our momentum from 2024, embecta began the year with solid ... revenues related to sales of non-diabetes products to Becton, Dickinson and Company ("BD") and $1.6 million of favorable ...